Mar 30, 2023 7:00am EDT Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in Fibromyalgia
Mar 27, 2023 7:00am EDT Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine Congress
Mar 23, 2023 4:15pm EDT Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit
Mar 23, 2023 7:00am EDT Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in Fibromyalgia
Mar 16, 2023 4:05pm EDT Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
Mar 16, 2023 7:00am EDT Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Mar 13, 2023 7:00am EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Mar 7, 2023 7:00am EST Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance”
